{
    "nct_id": "NCT05059327",
    "official_title": "A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children, Adolescents, and Young Adults With Uncontrolled Seizures Associated With Tuberous Sclerosis Complex",
    "inclusion_criteria": "Inclusion Criteria (summary):\n\n* Ability and willingness to provide informed assent or written consent or consent from their legal representative.\n* Fluency in the language of the study staff\n* Age 5 to 30 years at study entry\n* A documented history of TSC\n* Refractory seizure history\n* Currently receiving one or more anti-epileptic drugs (AEDs)\n* Stable medications or interventions for epilepsy\n* Willingness to complete Patient Reported Outcome assessments\n* For female patients of childbearing potential:\n\n  1. Willingness to undergo serum or urinary pregnancy testing at screening and during the trial period.\n  2. Willingness to use contraception.\n\nExclusion Criteria (summary):\n\n* Neurologic disease other than TSC\n* Recent anoxic episode\n* Patient weight below 15kg\n* Clinically significant unstable medical condition(s)\n* Pregnancy or lactation\nHealthy volunteers allowed\nMust have minimum age of 5 Years\nMust have maximum age of 30 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}